<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667156</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-I-112</org_study_id>
    <nct_id>NCT04667156</nct_id>
  </id_info>
  <brief_title>Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects</brief_title>
  <official_title>A Single-centre, Single Dose, Randomized, Open-label, Three Period, Six Sequence, Cross Controlled Study to Assess the Relative Bioavailability of the New and Traditional Formulations on SHR6390 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate relative bioavailability during the new and&#xD;
      traditional formulations of SHR6390 in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2020</start_date>
  <completion_date type="Actual">January 29, 2021</completion_date>
  <primary_completion_date type="Actual">January 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fr</measure>
    <time_frame>Day1~Day35</time_frame>
    <description>Relative bioavailability of the two new formulations on SHR6390</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1~Day35</time_frame>
    <description>Maximum concentration of SHR6390</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day1~Day35</time_frame>
    <description>Area under the concentration-time curve from time zero to time t of SHR6390</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Day1~Day35</time_frame>
    <description>Area under the concentration-time curve extrapolated to infinity of SHR6390</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 traditional formulation (R) in the last period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 new formulation 2 (T2) in the last period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 1 (T1) in the last period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 2 (T2) in the last period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 traditional formulation (R) in the last period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 new formulation 1 (T1) in the last period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390</intervention_name>
    <description>SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Execute an informed consent;&#xD;
&#xD;
          2. Male or female aged 18-45 years (including threshold) on the date of signing the&#xD;
             informed consent;&#xD;
&#xD;
          3. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) in the&#xD;
             range of 19.0-26.0 kg / m2 (including the critical value);&#xD;
&#xD;
          4. Physical examination, vital signs, laboratory examination , 12-Lead ECG, abdominal&#xD;
             B-ultrasound, chest X-ray, etc. are normal or abnormal, but the researcher has no&#xD;
             clinical significance according to NCI CTCAE 5.0 standard;&#xD;
&#xD;
          5. Fertile subjects had no family planning and had to take acceptable contraceptive&#xD;
             measures and no plans to donate eggs and sperm within 7 months from the date of&#xD;
             signing informed consent to the last medication; the serum pregnancy test of fertile&#xD;
             women within 72 hours before the first administration of the study drug should be&#xD;
             negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have previously suffered from primary diseases of important organs,&#xD;
             including but not limited to neuropsychiatric, cardiovascular, digestive tract,&#xD;
             respiratory system, urinary, endocrine, blood, immune and other diseases, which are&#xD;
             judged by the researchers to be unsuitable for the trial;&#xD;
&#xD;
          2. Patients who have received any previous operation affecting gastrointestinal&#xD;
             absorption;&#xD;
&#xD;
          3. Patients who had received any surgery within 6 months before screening, or planned to&#xD;
             undergo surgery during the study period;&#xD;
&#xD;
          4. Those who lost blood or donated more than 400 ml or received blood transfusion within&#xD;
             3 months before screening;&#xD;
&#xD;
          5. HBsAg positive, HCV antibody positive, HIV antibody positive, syphilis antibody&#xD;
             positive;&#xD;
&#xD;
          6. History of drug use or drug abuse, or drug screening positive;&#xD;
&#xD;
          7. Smoking and alcohol addict and unable to stop smoking during the test period; those&#xD;
             with positive alcohol screening; those with positive nicotine screening;&#xD;
&#xD;
          8. Allergic constitution, including severe drug allergy or drug allergy history; known&#xD;
             allergy to shr6390 tablets or its excipients;&#xD;
&#xD;
          9. Having swallowing resistance or disorder, affecting drug absorption;&#xD;
&#xD;
         10. Participated in other clinical trials and taken the study drug within 3 months before&#xD;
             taking the study drug for the first time;&#xD;
&#xD;
         11. Inducers or inhibitors of CYP3A4, CYP2C9 and CYP2C8 were taken within 4 weeks before&#xD;
             the first administration of study drug;&#xD;
&#xD;
         12. Taking any prescription drug, over-the-counter drug, traditional Chinese medicine or&#xD;
             food supplement within 2 weeks before taking the study drug for the first time;&#xD;
&#xD;
         13. Ingestion of grapefruit containing products, fruit juice, food or beverage containing&#xD;
             methylxanthine or alcohol within 72 hours before taking the study drug for the first&#xD;
             time; taking strenuous exercise; or having other factors affecting the absorption,&#xD;
             distribution, metabolism and excretion of drugs;&#xD;
&#xD;
         14. Lactating women;&#xD;
&#xD;
         15. The researchers considered that the subjects had any other factors that were not&#xD;
             suitable for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>470071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

